Conclusion

Adverse drug reactions impose a huge burden not only on the patient but also on the health-care system. With the narrow therapeutic index of most agents used to treat cancer and the marked heterogeneity observed across cancer patient populations, adverse drug reactions are a reality that must be dealt with. A better understanding of the clinical and genetic factors that influence the pharmacokinetic profile of a chemotherapeutic agent is needed to optimize drug-dosing regimens to obtain maximal efficacy with minimal toxicity. Moreover, promising advancements in the field of pharmacogenetics will enable the development of effective agents that will make their way to the clinic in a timely manner. With the remarkable rate of progress seen in the field of cancer therapeutics, the application of "personalized cancer chemotherapy" to routine clinical practice will be a reality in the not too distant future.

REFERENCES

1. Bordet R, Gautier S, Le Louet H, et al. Analysis of the direct cost of adverse drug reactions in hospitalized patients. Eur J Clin Pharmacol 2001; 56:935-941.

2. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487-491.

3. Jeffrey S, Ross MD, David P, et al. Pharmacogenomics. Adv Anat Pathol 2004; 11: 211-220.

4. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients—a meta-analysis of prospective studies. JAMA 1998; 279:12001205.

5. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 1995; 155:1949-1956.

6. Egorin M, Echo DV, Olman E, et al. Prospective validation of a pharmacologically based dosing scheme for the cisdiamminedichloroplatinum (II) analogue diamminecylobutane dicarboxylato platinum. Cancer Res 1985; 45:6502.

7. Calvert A, Newell D, Gumbrell L, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7:1748.

8. Lichtman SM, Hollis D, Miller AA, et al. Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol 2006; 24:1846-1851.

9. Sachidanadam R, Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001; 409:928-933.

10. Evans DA, Manley KA, McKusch VA, et al. Genetic control of isoniazid metabolism in man. Br Med J 1960; 2:485 -491.

11. Knight RA, Selin MJ, Harris HW, et al. Genetic factors influencing isoniazid blood levels in humans. Trans Conf Chemother Tuberc 1959; 8:52-56.

12. Evans DA. Survey of human acetylator polymorphism in spontaneous disorders. J Med Genet 1984; 21:243-253.

13. Ratain MJ, Mick R, Berezin F, et al. Paradoxical relationship between acetylator pheno-type and amonafide toxicity. Clin Pharmacol Ther 1991; 50:573 -579.

14. Pui C-H, Evans WE. Acute lymphoblastic leukemia. New Engl J Med 1998; 339: 605-615.

15. Krynetski EY, Tai HL, Yates CR, et al. Genetic polymorphisms of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996; 6:279-290.

16. McLeod HL, Coulthard S, Thomas AE, et al. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukemia. Br J Hematol 1999; 105:696-700.

17. Pui C-H, Relling MV, Cheng Cheng, et al. Thiopurine methyltransferase in acute lym-phoblastic leukemia. Blood 2006; 107:843-844.

18. Molloy AM, Daly S, Mills JL, et al. Thermolabile variant of 5,10-methylenetetrahydrofo-late reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet 1997; 349:1591-1593.

19. Franco RF, Simoes BP, Tone LG, et al. The methylenetetrahydrofolate reductase C677T gene polymorphism decreases the risk of childhood acute lymphocytic leukemia. Br J Haematol 2001; 115:616-618.

20. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 365: 1687-1717.

21. Lonning PE, Lien EA, Lundgren S, et al. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet 1992; 22:327-358.

22. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after co administration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95:1758-1764.

23. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339: 1609-1618.

24. Desta Z, Ward BA, Soukhova NV, et al. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D J Pharmacol Exp Ther 2004; 310:1062-1075.

25. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97:30-39.

26. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23:9312-9318.

27. Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irino-tecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101:847-854.

28. Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature 1957; 179:663-666.

29. Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994; 12:2248-2253.

30. McLeod HL, Collie-Duguid ES, Vreken P, et al. Nomenclature for human DPYD alleles. Pharmacogenetics 1998; 8:455-459.

31. Lu A, Zhang R, Diasio RB. Dihydropyrimadine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993; 53:5433-5438.

32. Raida M, Schwabe W, Hausler P, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 2001; 7:2832-2839.

33. Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 200; 18:299-313.

34. Leichman CG, Lenz HJ, Leichman L, et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997; 15: 3223-3229.

35. Horie N, Aiba H, Oguro K, et al. Functional analysis and DNA polymorphism of the tan-demly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20:191-197.

36. Marsh S, Mckay JA, Cassidy J, Mcleod HL. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 2001; 19:383-386.

37. Flochart DA. Pharmacogenomics in the endocrine treatment of breast cancer. San Antonio Breast Cancer Symposium, MINI Symposium 4; 2005.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment